TREATMENT OF NEUROTRAUMA USING ANTIBODIES TO LYSOPHOSPHATIDIC ACID

1 . A method of treating neurotrauma in a subject comprising administering to said subject a therapeutically effective amount of an antibody, or a fragment thereof, that binds lysophosphatidic acid, thereby treating the neurotrauma.

2 . The method of claim 1 wherein the neurotrauma is traumatic brain injury, stroke, brain or spinal cord hemorrhage, brain infarct, or spinal cord injury.

3 . The method of claim 2 wherein the treatment results in reduction or inhibition of brain hemorrhage, reduction or inhibition of brain infarct, reduction or inhibition of brain inflammation, reduction or inhibition of neurodegeneration, or improved functional recovery.

4 . The method of claim 3 wherein improved functional recovery is improved locomotion.

5 . A method according to claim 1 wherein the antibody or fragment thereof that binds lysophosphatidic acid is a monoclonal antibody, or fragment thereof.

6 . A method according to claim 5 wherein the monoclonal antibody or fragment thereof is a humanized monoclonal antibody or fragment thereof.

7 . The method of claim 1 wherein the subject is a human subject.

8 . The method of claim 6 wherein the antibody or LPA-binding fragment thereof comprises at least one immunoglobulin heavy chain variable domain comprising a first, second and third heavy chain complementarity determining region (CDR) and at least one immunoglobulin light chain variable domain comprising a first, second and third light chain CDR, wherein the first heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 11 or 17, the second heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 12, the third heavy chain CDR comprises the amino acid sequence of SEQ ID NO: 13, the first light chain CDR comprises the amino acid sequence of SEQ ID NO: 14, the second light chain CDR comprises the amino acid sequence of SEQ ID NO: 15, and the third light chain CDR comprises the amino acid sequence of SEQ ID NO: 16.

9 . The method of claim 8 wherein:

a. the at least one heavy chain variable domain comprises an amino acid sequence:

(SEQ ID NO: 61)

EVQLVQSGAEVKKPGESLKISCQAFGDAFTNYLIEWVRQMPGQGLEWIGL

IYPDSGYINYNENFKGQATLSADRSSSTAYLQWSSLKASDTAMYFCARRF

AYYGSGYYFDYWGQGTMVTVSS;

and

b. the at least one light chain variable domain comprises an amino acid sequence:

(SEQ ID NO: 42)

DVVMTQTPLSLPVTPGEPASISCRSSQSLLKTNGNTYLHWYLQKPGQSPK

LLIFKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFP

FTFGQGTKLEIK.

10 . The method according to claim 9 wherein the antibody or fragment thereof comprises:

a. two heavy chain variable domains each comprising an amino acid sequence:

(SEQ ID NO: 61)

EVQLVQSGAEVKKPGESLKISCQAFGDAFTNYLIEWVRQMPGQGLEWIGL

IYPDSGYINYNENFKGQATLSADRSSSTAYLQWSSLKASDTAMYFCARRF

AYYGSGYYFDYWGQGTMVTVSS;

and

b. two light chain variable domains each comprising an amino acid sequence:

(SEQ ID NO: 42)

DVVMTQTPLSLPVTPGEPASISCRSSQSLLKTNGNTYLHWYLQKPGQSPK

LLIFKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFP

FTFGQGTKLEIK.

11 . A method for reducing the size of a brain infarct in a subject having or suspected of having sustained a traumatic brain injury, comprising administering to said subject a therapeutically effective amount of an antibody, or fragment thereof, that binds lysophosphatidic acid, thereby reducing the size of said brain infarct, wherein the humanized antibody or fragment thereof comprises:

a. at least one heavy chain variable domain comprising an amino acid sequence:

(SEQ ID NO: 61)

EVQLVQSGAEVKKPGESLKISCQAFGDAFTNYLIEWVRQMPGQGLEWIGL

IYPDSGYINYNENFKGQATLSADRSSSTAYLQWSSLKASDTAMYFCARRF

AYYGSGYYFDYWGQGTMVTVSS;

and

b. at least one light chain variable domain comprising an amino acid sequence:

(SEQ ID NO: 42)

DVVMTQTPLSLPVTPGEPASISCRSSQSLLKTNGNTYLHWYLQKPGQSPK

LLIFKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFP

FTFGQGTKLEIK.

12 . The method according to claim 11 wherein the subject is a human subject.

13 . The method according to claim 11 wherein the humanized antibody or fragment thereof comprises:

a. two heavy chain variable domains each comprising an amino acid sequence:

(SEQ ID NO: 61)

EVQLVQSGAEVKKPGESLKISCQAFGDAFTNYLIEWVRQMPGQGLEWIGL

IYPDSGYINYNENFKGQATLSADRSSSTAYLQWSSLKASDTAMYFCARRF

AYYGSGYYFDYWGQGTMVTVSS;

and

b. two light chain variable domains each comprising an amino acid sequence:

(SEQ ID NO: 42)

DVVMTQTPLSLPVTPGEPASISCRSSQSLLKTNGNTYLHWYLQKPGQSPK

LLIFKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFP

FTFGQGTKLEIK.

14 . A method for of increasing locomotor function in a subject having sustained a neurotrauma resulting in a decrease in locomotor function, comprising administering to said subject a therapeutically effective amount of an antibody, or fragment thereof, that binds lysophosphatidic acid, thereby increasing the locomotor function of the subject, wherein the humanized antibody or fragment thereof comprises:

a. at least one heavy chain variable domain comprising an amino acid sequence:

(SEQ ID NO: 61)

EVQLVQSGAEVKKPGESLKISCQAFGDAFTNYLIEWVRQMPGQGLEWIGL

IYPDSGYINYNENFKGQATLSADRSSSTAYLQWSSLKASDTAMYFCARRF

AYYGSGYYFDYWGQGTMVTVSS;

and

b. at least one light chain variable domain comprising an amino acid sequence:

(SEQ ID NO: 42)

DVVMTQTPLSLPVTPGEPASISCRSSQSLLKTNGNTYLHWYLQKPGQSPK

LLIFKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFP

FTFGQGTKLEIK.

15 . The method according to claim 14 wherein the subject is a human subject.

16 . The method according to claim 14 wherein the humanized antibody or fragment thereof comprises:

a. two heavy chain variable domains each comprising an amino acid sequence:

(SEQ ID NO: 61)

EVQLVQSGAEVKKPGESLKISCQAFGDAFTNYLIEWVRQMPGQGLEWIGL

IYPDSGYINYNENFKGQATLSADRSSSTAYLQWSSLKASDTAMYFCARRF

AYYGSGYYFDYWGQGTMVTVSS;

and

b two light chain variable domains each comprising an amino acid sequence:

(SEQ ID NO: 42)

DVVMTQTPLSLPVTPGEPASISCRSSQSLLKTNGNTYLHWYLQKPGQSPK

LLIFKVSNRFSGVPDRFSGSGSGTDFTLKISRVEAEDVGVYFCSQSTHFP

FTFGQGTKLEIK.